Abstract
Mesenchymal stromal cells (MSCs) are currently under investigation for the treatment of inflammatory bowel disease (IBD), including Crohn's disease. The models of colitis induced by intrarectal infusion of 2,4,6-trinitrobenzene sulfonic acid (TNBS) or by oral administration of dextran sulfate sodium (DSS) in susceptible mouse strains have been commonly used as preclinical tools to demonstrate the efficiency of treatments with MSCs isolated from various sources. Both models are being and will be critical to improve MSC-based therapies in human IBD by assaying new pathways, therapeutic regimes and tissue targeting strategies. Here, we describe our experiences in the treatment of acute and chronic TNBS- and DSS-induced colitis with MSCs.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
